封面
市場調查報告書
商品編碼
1460775

醫藥中間體市場 - 全球產業規模、佔有率、趨勢、機會和預測,按產品、應用、地區和競爭細分,2019-2029F

Pharmaceutical Intermediates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2019-2029F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球醫藥中間體市場估值為 413.5 億美元,預計在預測期內將強勁成長,到 2029 年CAGR為5.53%。醫藥中間體在複雜的藥品製造過程中發揮關鍵作用,因為它們確保安全性和有效性。這些關鍵成分可作為重要的組成部分,促進對製藥業至關重要的活性藥物成分 (API) 的生產。

由於全球慢性病盛行率不斷上升,對醫藥中間體的需求持續成長。隨著需要治療的患者數量的增加,對高效、可靠的藥物合成的需求也在增加。然而,這個新興市場並非沒有挑戰。

嚴格的法規構成了重大障礙,要求製造商遵守嚴格的指導方針和品質標準。此外,與研發相關的高投資成本以及藥物開發過程的複雜性可能會阻礙市場成長。

儘管如此,製藥業的蓬勃發展依賴創新和技術進步。隨著藥物生產過程中出現新的方法和技術,它們為市場擴張提供了有利可圖的機會。此外,產業主要參與者之間的策略合作和夥伴關係預計將進一步推動市場成長,促進創新和推動進步。

主要市場促進因素

藥品需求不斷成長

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:COVID-19 對全球醫藥中間體市場的影響

第 5 章:全球醫藥中間體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依產品(化學中間體、原料藥中間體、客製化中間體、其他)
    • 依用途分類(鎮痛藥、抗發炎藥、心血管藥、抗糖尿病藥、抗癌藥、其他)
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章:亞太地區醫藥中間體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品分類
    • 按申請
    • 按國家/地區
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章:歐洲醫藥中間體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品分類
    • 按申請
    • 按國家/地區
  • 歐洲:國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章:北美醫藥中間體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品分類
    • 按申請
    • 按國家/地區
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章:南美洲醫藥中間體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品分類
    • 按申請
    • 按國家/地區
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲醫藥中間體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按產品分類
    • 按申請
    • 按國家/地區
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 促進要素
  • 挑戰

第 12 章:市場趨勢發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章:全球醫藥中間體市場:SWOT 分析

第 14 章:波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章:大環境分析

第16章:競爭格局

  • Aceto Corporation
  • BASF SE
  • Chiracon GmbH
  • Yin-sheng Bio-tech Co. Ltd.
  • Dishman Pharmaceuticals Chemicals Ltd
  • Green Vision Life Sciences Pvt Ltd
  • Midas Pharma GmbH
  • Sanofi SA
  • Vertellus Holdings LLC.
  • Lonza Group AG

第 17 章:策略建議

第 18 章:關於我們免責聲明

簡介目錄
Product Code: 23413

Global Pharmaceutical Intermediates Market was valued at USD41.35 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.53% through 2029. Pharmaceutical intermediates play a critical role in the complex process of drug manufacturing as they ensure both safety and efficacy. These key components act as essential building blocks, facilitating the production of active pharmaceutical ingredients (APIs) that are vital for the pharmaceutical industry.

The demand for pharmaceutical intermediates is continuously on the rise, driven by the increasing prevalence of chronic diseases worldwide. As the number of patients requiring treatment grows, so does the need for efficient and reliable drug synthesis. However, this burgeoning market is not free from challenges.

Stringent regulations pose a significant obstacle, requiring manufacturers to adhere to strict guidelines and quality standards. Additionally, the high investment costs associated with research and development, along with the complexities involved in the drug development process, can potentially hinder market growth.

Nevertheless, the pharmaceutical industry thrives on innovation and technological advancements. As new methods and techniques emerge in drug manufacturing processes, they present lucrative opportunities for market expansion. Moreover, strategic collaborations and partnerships among key players in the industry are anticipated to further fuel market growth, fostering innovation and driving advancements.

Key Market Drivers

Growing Demand for Pharmaceuticals

The global pharmaceutical intermediates market is experiencing significant growth, driven by an increasing demand for pharmaceuticals. Pharmaceutical intermediates, which are essential compounds used in the production of active pharmaceutical ingredients (APIs), play a crucial role in ensuring drug safety and efficacy.

The growing demand for pharmaceuticals is primarily fueled by the rising global healthcare needs and the prevalence of chronic diseases. As the global population continues to grow and age, the need for effective and affordable medications becomes increasingly important. This trend has led to a surge in the need for pharmaceutical intermediates, setting the stage for significant market expansion.

Additionally, increasing investment in research and development is another major driver of the pharmaceutical intermediates market. With more resources allocated to discovering new drugs and improving existing ones, the demand for high-quality intermediates that can facilitate the development of innovative pharmaceuticals is set to rise further.

Furthermore, the growth in the pharmaceutical industry as a whole is also fueling the demand for pharmaceutical intermediates. As new drugs are discovered and existing ones are optimized, there is an increased requirement for these essential compounds that form the backbone of the pharmaceutical manufacturing process. Moreover, the booming chemical industry, which is closely intertwined with the pharmaceutical sector, is driving demand for pharmaceutical intermediates across the world.

Advancements in Manufacturing Process

Technological advancements have revolutionized the manufacturing process of pharmaceutical intermediates, making it more efficient and cost-effective. For instance, the introduction of continuous flow chemistry in pharmaceutical production has transformed the traditional manufacturing process. This innovative technology allows for the continuous production of pharmaceutical intermediates, eliminating the need for batch processing and significantly reducing production time. By enabling a continuous flow of reactions, this approach not only improves the speed of production but also minimizes the risk of cross-contamination and increases the overall yield of high-quality intermediates.

Furthermore, the use of artificial intelligence (AI) and machine learning (ML) technologies in the manufacturing process has had a profound impact on pharmaceutical intermediate production. These advanced technologies provide predictive analysis for better decision-making, optimizing production processes and improving quality control. AI algorithms can analyze vast amounts of data to identify trends, patterns, and potential issues, allowing for proactive adjustments and efficient resource allocation. Similarly, ML models can continuously learn from data, leading to continuous process improvement and enhanced product quality.

The integration of these technologies into the manufacturing process is driving the demand for pharmaceutical intermediates as companies strive to leverage the benefits of increased efficiency, improved quality, and reduced costs. The pharmaceutical industry is embracing these advancements to stay competitive in a rapidly evolving market, ensuring the timely and cost-effective production of essential medications for patients worldwide.

Key Market Challenges

Surge in Regulatory Compliance

Pharmaceutical intermediates, which are crucial components used in the production of active pharmaceutical ingredients (APIs), play a vital role in meeting stringent safety and efficacy standards. As the pharmaceutical industry continues to globalize, companies are actively seeking competitive advantages across various regions, particularly in Asia. This expansion, however, brings about a higher level of complexity in terms of regulatory compliance.

Regulations governing pharmaceutical intermediates vary across countries, and the lack of dedicated local compliance resources poses a significant risk for global companies. Navigating these diverse regulations while ensuring the production of high-quality pharmaceutical intermediates presents a key challenge. This challenge is further compounded by the constant evolution of regulatory requirements, which adds another layer of complexity to the compliance landscape.

In order to streamline regulatory processes, one potential approach could be the implementation of supplier-agnostic regulatory filing specifications. Such an approach could simplify compliance efforts. However, until such changes are fully implemented, companies must continue to adapt to the existing regulatory frameworks.

Furthermore, the development and manufacturing of advanced therapies, such as cell and gene therapies, present a significant challenge. As the pipelines for these innovative treatments continue to expand, the demand for pharmaceutical intermediates increases accordingly. However, the complex and ever-evolving regulatory landscape can potentially slow down the development process, thus limiting the availability of these promising therapies.

Key Market Trends

Increasing Demand for Generic Drugs

Pharmaceutical intermediates play a crucial role in the production of generic drugs, serving as vital building blocks for their synthesis. With the increasing demand for affordable healthcare solutions, the importance of pharmaceutical intermediates continues to rise. This has led major pharmaceutical companies to focus on expanding their portfolio of generic drugs, thereby further fueling the demand for these intermediates.

Moreover, the pharmaceutical intermediates industry is witnessing several noteworthy trends and dynamics. One such trend is the significant growth in the pharmaceutical sector, driven by advancements in medical science and technology. Additionally, there is an increased emphasis on research and development to discover novel therapeutic solutions and improve existing drug formulations. This research-driven approach is fostering innovation and propelling the demand for pharmaceutical intermediates.

Furthermore, the rising prevalence of chronic diseases globally has created a pressing need for both innovative and generic drugs. Pharmaceutical intermediates play a pivotal role in the development of these drugs, enabling the production of effective and affordable medications to combat various diseases and improve patient outcomes. This ever-increasing demand for pharmaceutical intermediates reflects the ongoing pursuit of improved healthcare solutions worldwide.

Segmental Insights

Product Insights

Based on the category of product, the bulk drug intermediates segment emerged as the dominant player in the global market for pharmaceutical intermediates in 2023. Bulk drug intermediates play a crucial role in the pharmaceutical industry as they are extensively utilized in the production of active pharmaceutical ingredients (API). These APIs are the essential components that deliver the desired therapeutic effects in various drugs. Furthermore, to foster the growth of this segment, several government initiatives have been introduced to promote and develop bulk drug parks.

As an instance, the Department of Pharmaceuticals has prioritized a comprehensive list of 56 APIs under the Make-in-India initiative, emphasizing the nation's commitment to self-sufficiency in the pharmaceutical sector. These initiatives aim to boost domestic manufacturing capabilities, create employment opportunities, and enhance the overall accessibility of vital drugs for the population.

Application Insights

The analgesics segment is projected to experience rapid growth during the forecast period. Analgesics, commonly known as pain relievers, are extensively used to alleviate various types of pain. With the increasing prevalence of chronic ailments such as arthritis, cancer, and cardiovascular diseases, the demand for analgesics is on the rise. These conditions, characterized by long-lasting pain and discomfort, necessitate effective pain management strategies. As a result, the analgesics market is experiencing significant growth as healthcare providers and patients seek reliable solutions to address pain and improve quality of life.

Regional Insights

North America emerged as the dominant player in the Global Pharmaceutical Intermediates Market in 2023, holding the largest market share in terms of value. This is primarily due to the presence of numerous pharmaceutical companies, renowned research centers and laboratories, and the rapid expansion of Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) in the United States and Canada. Furthermore, the biopharmaceutical industry in North America is expected to maintain its dominant position throughout the forecast period, supported by increasing investments from both the government and private sector players. These investments aim to stimulate the growth and innovation of the industry, fostering advancements in drug development, clinical research, and healthcare solutions.

Key Market Players

Aceto Corporation

BASF SE

Chiracon GmbH

Yin-sheng Bio-tech Co. Ltd.

Dishman Pharmaceuticals Chemicals Ltd

Green Vision Life Sciences Pvt Ltd

Midas Pharma GmbH

Sanofi SA

Vertellus Holdings LLC.

Lonza Group AG

Report Scope:

In this report, the Global Pharmaceutical Intermediates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Intermediates Market,By Product:

  • Chemical Intermediates
  • Bulk Drug Intermediates
  • Custom Intermediates
  • Others

Pharmaceutical Intermediates Market,By Application:

  • Analgesics
  • Anti-inflammatory Drug
  • Cardiovascular Drugs
  • Anti-Diabetic Drugs
  • Anti-Cancer Drugs
  • Others

Pharmaceutical Intermediates Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Intermediates Market.

Available Customizations:

Global Pharmaceutical Intermediates Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Impact of COVID-19 on Global Pharmaceutical Intermediates Market

5.Global Pharmaceutical Intermediates Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Product (Chemical Intermediates, Bulk Drug Intermediates, Custom Intermediates, Others)
    • 5.2.2.By Application (Analgesics, Anti-inflammatory Drug, Cardiovascular Drugs, Anti-Diabetic Drugs, Anti-Cancer Drugs, Others)
    • 5.2.3.By Region
    • 5.2.4.By Company (2023)
  • 5.3.Market Map

6.Asia Pacific Pharmaceutical Intermediates Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Product
    • 6.2.2.By Application
    • 6.2.3.By Country
  • 6.3.Asia Pacific: Country Analysis
    • 6.3.1.China Pharmaceutical Intermediates Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Product
        • 6.3.1.2.2.By Application
    • 6.3.2.India Pharmaceutical Intermediates Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Product
        • 6.3.2.2.2.By Application
    • 6.3.3.Australia Pharmaceutical Intermediates Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Product
        • 6.3.3.2.2.By Application
    • 6.3.4.Japan Pharmaceutical Intermediates Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Product
        • 6.3.4.2.2.By Application
    • 6.3.5.South Korea Pharmaceutical Intermediates Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Product
        • 6.3.5.2.2.By Application

7.Europe Pharmaceutical Intermediates Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Product
    • 7.2.2.By Application
    • 7.2.3.By Country
  • 7.3.Europe: Country Analysis
    • 7.3.1.France Pharmaceutical Intermediates Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Product
        • 7.3.1.2.2.By Application
    • 7.3.2.Germany Pharmaceutical Intermediates Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Product
        • 7.3.2.2.2.By Application
    • 7.3.3.Spain Pharmaceutical Intermediates Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Product
        • 7.3.3.2.2.By Application
    • 7.3.4.Italy Pharmaceutical Intermediates Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.By Product
        • 7.3.4.2.2.By Application
    • 7.3.5.United Kingdom Pharmaceutical Intermediates Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.By Product
        • 7.3.5.2.2.By Application

8.North America Pharmaceutical Intermediates Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Product
    • 8.2.2.By Application
    • 8.2.3.By Country
  • 8.3.North America: Country Analysis
    • 8.3.1.United States Pharmaceutical Intermediates Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Product
        • 8.3.1.2.2.By Application
    • 8.3.2.Mexico Pharmaceutical Intermediates Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Product
        • 8.3.2.2.2.By Application
    • 8.3.3.Canada Pharmaceutical Intermediates Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Product
        • 8.3.3.2.2.By Application

9.South America Pharmaceutical Intermediates Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Product
    • 9.2.2.By Application
    • 9.2.3.By Country
  • 9.3.South America: Country Analysis
    • 9.3.1.Brazil Pharmaceutical Intermediates Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Product
        • 9.3.1.2.2.By Application
    • 9.3.2.Argentina Pharmaceutical Intermediates Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Product
        • 9.3.2.2.2.By Application
    • 9.3.3.Colombia Pharmaceutical Intermediates Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Product
        • 9.3.3.2.2.By Application

10.Middle East and Africa Pharmaceutical Intermediates Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Product
    • 10.2.2.By Application
    • 10.2.3.By Country
  • 10.3.MEA: Country Analysis
    • 10.3.1.South Africa Pharmaceutical Intermediates Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Product
        • 10.3.1.2.2.By Application
    • 10.3.2.Saudi Arabia Pharmaceutical Intermediates Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Product
        • 10.3.2.2.2.By Application
    • 10.3.3.UAE Pharmaceutical Intermediates Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Product
        • 10.3.3.2.2.By Application

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Recent Developments
  • 12.2.Product Launches
  • 12.3.Mergers Acquisitions

13.Global Pharmaceutical Intermediates Market: SWOT Analysis

14.Porter's Five Forces Analysis

  • 14.1.Competition in the Industry
  • 14.2.Potential of New Entrants
  • 14.3.Power of Suppliers
  • 14.4.Power of Customers
  • 14.5.Threat of Substitute Product

15.PESTLE Analysis

16.Competitive Landscape

  • 16.1.Aceto Corporation
    • 16.1.1.Business Overview
    • 16.1.2.Company Snapshot
    • 16.1.3.Products Services
    • 16.1.4.Financials (As Reported)
    • 16.1.5.Recent Developments
  • 16.2.BASF SE
  • 16.3.Chiracon GmbH
  • 16.4.Yin-sheng Bio-tech Co. Ltd.
  • 16.5.Dishman Pharmaceuticals Chemicals Ltd
  • 16.6.Green Vision Life Sciences Pvt Ltd
  • 16.7.Midas Pharma GmbH
  • 16.8.Sanofi SA
  • 16.9.Vertellus Holdings LLC.
  • 16.10.Lonza Group AG

17.Strategic Recommendations

18. About Us Disclaimer